Last $30.55 USD
Change Today +2.48 / 8.84%
Volume 343.2K
PRTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

25 - 28 North Wall Quay

Dublin, 1

Ireland

Phone: 353 1 902 3519

Fax: 353 1 902 3510

Prothena Corporation plc, a biotechnology company, focuses on the discovery and development of novel antibodies for the potential treatment of a range of diseases that involve protein misfolding or cell adhesion. The company focuses on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. These potential therapies have a range of indications, including AL and AA forms of amyloidosis, Parkinson’s disease and related synucleinopathies, and novel cell adhesion targets involved in inflammatory disease and metastatic cancers. Research and Development Pipeline The company’s research and development pipeline includes three lead therapeutic antibody programs: NEOD001; PRX002; and PRX003. The company’s pipeline also includes two late discovery stage programs for which it is testing efficacy of antibodies in preclinical models of disease: tau antibodies for potential treatment of Alzheimer’s disease and antibodies for the potential treatment of type 2 diabetes. The company is also generating additional novel antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro. Lead Programs NEOD001 for Amyloidosis: NEOD001 is a monoclonal antibody that specifically targets the amyloid that accumulates in both AL and AA forms of amyloidosis. An Investigational New Drug application (IND) for NEOD001 in systemic amyloidosis (AL and AA forms of amyloidosis) was filed and accepted by the United States Food and Drug Administration in 2012. The company plans to initiate a Phase 1 clinical trial for NEOD001 in this indication. The primary objectives of the Phase 1 trial are to evaluate safety and tolerability of NEOD001 and determine a recommended dose for testing NEOD001 in Phase 2 trials. PRX002 for Parkinson’s disease: The company is developing PRX002, a monoclonal antibody targeting synuclein for the potential treatment of Parkinson’s disease and other synucleinopathies. PRX002 has advanced into manufacturing and is advancing into preclinical safety testing and anticipate that the company would file an IND and initiate a Phase 1 trial of PRX002 for Parkinson’s disease in 2014. PRX003 for Inflammatory Disease and Metastatic Cancer: The company is developing PRX003, a monoclonal antibody targeting melanoma cell adhesion molecule for the potential treatment of inflammatory disease and metastatic cancer. The company intends to advance PRX003 into manufacturing and preclinical safety testing. Discovery Programs Tau antibodies for Alzheimer’s disease: The company is developing antibodies targeting tau for the potential treatment of Alzheimer’s disease and other tauopathies. The company has generated and tested in vivo various proprietary tau antibodies. The company is selecting optimal candidates for their ability to block propagation and toxicity associated with misfolded forms in animal models of tauopathies. Antibodies for Type 2 diabetes: The company is developing antibodies to protect against loss of insulin producing beta cells of the pancreas for the potential treatment of type 2 diabetes. The company has generated antibodies and is testing the hypothesis that treatment with these antibodies may reduce the progressive increase in glucose levels in animal models of type 2 diabetes. Strategy The company’s strategy is to apply its extensive expertise in generating novel therapeutic antibodies and work with collaborators having expertise in specific animal models of disease; and to identify antibody candidates for clinical development. Key elements of the company’s strategy include continue to discover potential therapeutic antibodies directed against novel targets involved in protein misfolding and cell adhesion; translate its research discoveries into clinical development; establish early clinical proof of concept with its therapeutic antibodies; strategically collaborate or out-license select programs; and collaborate with scientific and clinical experts in disease areas of interest. Patents and Intellectual Property Rights In connection with its program targeting AL

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTA:US $30.55 USD +2.48

PRTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTA.
View Industry Companies
 

Industry Analysis

PRTA

Industry Average

Valuation PRTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 966.8x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 728.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit www.prothena.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.